Novo Nordisk Swaps Out Last Cancer Compound For Anti-Inflammatory
This article was originally published in The Pink Sheet Daily
Executive Summary
Refocused Danish pharma drops its inhaled-insulin portfolio, while swapping last oncologic for an anti-inflammatory.